News | July 24, 2024
Syngene reports drop in Q1 FY25 revenue to Rs. 790 Cr
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
ProtocolCopilot leverages advanced artificial intelligence to streamline the process of understanding and adhering to clinical research protocols
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Ibara will drive AI-powered clinical research innovation
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Subscribe To Our Newsletter & Stay Updated
